TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Multimodal Care for Cystectomy Frail Patient

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent as documented by signature (Appendix Informed Consent Form)~* ≥ 75 years old~* Fried frailty score ≥2~* Cystectomy with urinary diversion~* No contra-indication for spinal or epidural anesthesia~Exclusion Criteria:~* Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product,~* Women who are pregnant or breast feeding (not applicable as recruitment concerns patients with ≥75 yrs of age)~* Known or suspected non-compliance, drug or alcohol abuse,~* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,~* Enrolment of the investigator, his/her family members, employees and other dependent persons,~* Specific exclusions for the disease under study,~* Specific concomitant therapy washout requirements prior to and/or during study participation,~* Dietary restrictions: milk allergy~* Refusal to regional anesthesia~* Risk of aspiration~* Oral fluid restriction due to any reasons (severe renal insufficiency i.e. GFR \< 20ml/min)

- Gender: ALL
- Minimum Age: 75 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): 1. Around 2 to 4 weeks before surgery:~   * Fried frailty score~  * CARE score assessment~  * NRS Kondrup assessment~  * Plasma albumin and CRP values~  * Start with daily oral whey protein administration until evening before surgery45~2. Around 5-7 days before surgery:~   - Start with immunonutrition~3. Evening before surgery:~   * CARE score assessment~  * NRS Kondrup~  * CERAD cognition test assessment~  * Plasma albumin and CRP values, urine specific gravity~  * Carbohydrate loading~  * If urine specific gravity is \>1.020 then additional tap water drinking will be encouraged~4. Day of surgery:~   * Carbohydrate loading~  * Start anesthesia with spinal anesthesia (continuous)~5. POD 7:~   * CARE assessment~  * CERAD assessment~  * Plasma albumin and CRP values~6. POD14:~   * CARE assessment~  * Plasma albumin and CRP value~7. POD 30:~   * CARE assessment~  * NRS Kondrup~  * CERAD assessment~  * Plasma albumin and CRP values~8. POD 90:~   * CARE assessment~  * NRS Kondrup~  * CERAD assessment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Infiltration Effect on SUV

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with solid tumors undergoing PET/CT scan who have at least one measurable target lesion and sustain a moderate or greater infiltration.~Exclusion Criteria:~* Subjects unwilling or unable to tolerate a repeat PET/CT scan.~* Subjects with meaningful medical intervention between PET/CT scans that would likely impact SUV.~* Subjects with follow up injection infiltrations that would likely impact the SUV.~* Pregnant patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infiltration (Type: EXPERIMENTAL): Repeat F-18 FDG PET

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-breastfeeding Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Postpartum women who:~* Smoked \>1 cigarette in last month of pregnancy~* Deliver a baby at Brigham and Women's Hospital in Boston, MA~* Do not breastfeed or plan to breastfeed.~* Want to attempt to stop smoking~Exclusion Criteria:~* Age \<18 years;~* Current use of bupropion or antidepressant;~* Current major depression or other severe psychiatric illness (e.g., schizophrenia, mania);~* Contraindication to use of bupropion;~* Illegal substance use in past 6 months;~* \>1 drink/day of alcohol during pregnancy;~* Newborn with major congenital anomaly or \<25 weeks' gestation;~* Inability to speak or read English;~* No telephone.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Sugar pill
- Bupropion SR (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cord Blood Transplantation for Patients With Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory acute leukemia (myeloid or lymphoid)~* Acute leukemia in first remission at high-risk for recurrence~* Chronic myelogenous leukemia in accelerated phase or blast-crisis~* Chronic myelogenous leukemia in chronic phase~* Recurrent or refractory malignant lymphoma or Hodgkin lymphoma~* Chronic lymphocytic leukemia, relapsed or with poor prognostic features~* Multiple myeloma~* Myelodysplastic syndrome~* Chronic myeloproliferative disease~* Hemoglobinopathies~* Aplastic anemia~Exclusion Criteria:~* Zubrod performance status \> 2~* Life expectancy is severely limited by concomitant illness~* Patients with severely decreased LVEF or impaired pulmonary function tests~* Estimated Creatinine Clearance \<50 ml/min~* Serum bilirubin\> 2.0 mg/dl or SGPT \>3 x upper limit of normal~* Evidence of chronic active hepatitis or cirrhosis~* HIV-positive~* Patient is pregnant~* Patient or guardian not able to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conditioning Regimen I (Type: EXPERIMENTAL): Arm I contains fludarabine, melphalan, and antithymocyte globulin (ATG)
- Conditioning Regimen II (Type: EXPERIMENTAL): Arm II contains fludarabine, busulfan, antithymocyte globulin (ATG), and total body irradiation (TBI).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Sedation With Third Molar Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiology (ASA) physical status I and II~* Four asymptomatic third molars indicated for removal~Exclusion Criteria:~* Clinical history or ECG evidence of:~  * cardiac dysrhythmia or heart block~ * ischemic heart disease~ * asthma~ * sleep apnea~ * impaired liver, renal, or mental function~* chronic sedative or analgesic use~* allergies to any of the study drugs~* history of pericoronal infection with third molars

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Dex plus midazolam (Type: ACTIVE_COMPARATOR): Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg i.v.
- Dex plus midazolam and ketamine (Type: ACTIVE_COMPARATOR): Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg and 0.25 mg/kg ketamine i.v.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Demonstrate the Effectiveness of Fecal Microbiota Transplantation for Selective Intestinal Decolonization of Patients Colonized by Carbapenemase-producing Klebsiella Pneumoniae

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age\> = 18 years.~* Signature of the informed consent by the patient or legally designated person~* Absence of active infection by carbapenemase-type KPC-producing Klebsiella pneumoniae at the time of assessment as well as in the month prior to inclusion in the study~Exclusion Criteria:~* Terminal situation, or estimated life expectancy of less than 3 months~* Pregnant or lactating women~* Intolerance or inability to take oral medication at the time of assessment~* History of aspiration or dysphagia~* Patients with a history of colectomy, colostomy or ileostomy~* Patients who are receiving or have received antibiotics in the month prior to the inclusion assessment~* Neutrophil count less than 500 cells / mm3~* Anticipation of the use of myelosuppressive treatment (eg. dexamethasone, chemotherapy against to solid tumors or prior to transplantation of hematopoietic progenitories) within 30 days after inclusion in the study~* Hematopoietic stem cell transplantation in the month prior to inclusion in the study~* Presence of clinical signs of mucositis~* Forecast of major abdominal surgical intervention in the month following inclusion in the study~* Patients with a Gianella Score\> 12 points~* History of having received decolonization guidelines in the previous 3 months~* Severe food allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fecal microbiota transplantation (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of Neurostimulation as a Tool for Reconditioning the Neuromuscular System of Patients Admitted to the ICU for Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Admitted to the ICU for :~  * Sepsis as defined by the presence of an infection, of known or suspected origin + organ dysfunction with a SOFA score ≥ 2~ * Or septic shock defined by sepsis with persistent hypotension requiring vasopressors to maintain mean artérial blood pressure ≥ 65 mmHg and serum lactate level \> 2 mmol/l despite adequate vascular filling~* After obtaining informed consent from a relative/trusted person or patient included in an emergency situation~* Patient affiliated to national health insurance.~Exclusion Criteria:~* Patient with a contraindication to the application of ES (e.g. pacemaker, defibrillator)~* Patient with a diagnosis of deep vein thrombosis and/or pulmonary embolism, confirmed and treated within the last 48 hours~* Patient with cardiac arrest prior to study inclusion~* Patient for whom a decision to limit or stop treatment has been made by the medical team~* Patients with a very poor prognosis in the very short term due to major co-morbidities (Child Pugh score C cirrhosis, terminal cancer, neuro-evolutionary disease with no treatment plan...)~* Patients with known neuro-orthopaedic and sensory disorders prior to inclusion, whether of originating in the spinal cord, nerve or brain.~* Person subject to a legal protection measure (curatorship, guardianship)~* Pregnant, parturient or breastfeeding women.~Secondary Exclusion Criteria:~- Patients receiving curare therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard support (Type: ACTIVE_COMPARATOR): None
- Standard treatment coupled with electro-stimulation sessions (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bone Demineralization Lesions in the Injured Marrow: Efficacy and Tolerability of Administration Early and Repeated the Zoledronic Acid. Comparative Study, Prospective, Double-blind Controlled (DBMZol)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Being diagnosed with a spinal cord injury less than 12 weeks of etiology stable,~* level of injury C5 L2,~* AIS grade A to D.~* Female or male between 18 and 45 years.~* No pregnancy.~* No osteoporosis.~* Good oral health.~* Good glomerular filtration.~* No cons-indication to Zoledronic Acid.~* No drugs affecting bone metabolism~Exclusion Criteria:~* pregnancy.~* osteoporosis.~* cons-indication to Zoledronic Acid.~* drugs affecting bone metabolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Zoledronic acid (Type: ACTIVE_COMPARATOR): Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times over two years.
- NACL (Type: PLACEBO_COMPARATOR): NACl 100 ml IV. 3 infusions. Administration 3 times over two years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients (\> 14 years) with suspected severe leptospirosis~* patients who presented with acute fever (oral temperature more than 38.00 C for \<15 days) in the absence of an obvious focus of infection~* In the opinion of the attending physician might have pulmonary hemorrhage (i.e. history of hemoptysis, and/ or bilateral nodular or air space infiltration).~Exclusion Criteria:~* pregnant or breastfeeding~* those with history of bleeding disorder~* those who had underlying diseases such as chronic liver disease, diabetes mellitus~* those who received diuretic or glucocorticoid

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): Standard supportive care
- 2 (Type: EXPERIMENTAL): Dexamethasone treatment
- 3 (Type: EXPERIMENTAL): Desmopressin treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 19 to 90 years~* On haemodialysis for the past 18 months prior to baseline~* Treatment with IV iron sucrose during the past 6 months according to the respective Summary of Product Characteristics (SmPC)~* Treatment with epoetin beta during the past 6 months according to the respective SmPC~* Regular Hb measurements and at least 5 (standard of care, approximately monthly) Hb measurements during the past 6 months~* Ferritin measurements during the past 6 months (at least 2 measurements)~* Signed informed consent~Exclusion Criteria:~* Life expectancy \<6 months~* One or more Hb measurements \<8 g/dl during the control period~* Living-donor transplant scheduled within the next 6 months~* Scheduled for switch to peritoneal dialysis or home haemodialysis~* Blood transfusion during the past 9 months~* Pregnancy or breast feeding~* Active infection~* Current malignancy or haematological disorder~* Previous severe hypersensitivity reaction to IV iron sucrose~* Serious allergic reactions to darbepoetin alfa or epoetin alfa/beta/zeta, respectively~* Current treatment with PEGylated erythropoietin~* Surgery in the past 6 months~* Surgery scheduled within the next 6 months~* Participation in a clinical trial in the past 7 months

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Anemia Control Model IV iron and ESA (Type: EXPERIMENTAL): Anemia Control Model (ACM) algorithm to recommend monthly IV and ESA dose over a 6 month period~IV iron: given monthly as required - dosing recommendation by ACM over 6 a month period~Erythropoiesis-Stimulating Agent (ESA): given monthly as required - dosing recommendation by ACM over 6 a month period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 70 years of age or older~* Undergoing elective abdominal, gynecological, or urological surgery requiring post-operative hospitalization and with an expected anesthesia time of 60 minutes or more~* Seen in pre-operative clinic of Maisonneuve-Rosemont hospital~Exclusion Criteria:~* Known dementia or other cognitive impairment~* Psychiatric disease~* Significant hearing or vision impairment~* Inability to communicate in French~* Allergy or other contraindication to medications in standardized anesthesia protocol

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observational cohort (Type: None): Adults 70 years of age or older undergoing major noncardiac surgery under protocolized general anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with cirrhosis and diagnosis of HRS type 1 or 2,serum creatinine \> 2.5 mg/dl~Exclusion Criteria:~* Diagnosis of HCC with a staging beyond the Milan Criteria di Milano~* Septic shock (systolic arterial pressure \< 90 mmHg~* Significant heart or respiratory failure~* Peripheral arteriophaty clinically significant~* Previous heart stroke or significant alteration of the ECG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Fifty patients with cirrhosis and HRS will be randomly assigned to arm 1.
- 2 (Type: EXPERIMENTAL): Fifty patients with cirrhosis and HRS will be randomly assigned to arm 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Detection no Invasive of a Silent Myocardial Ischemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* With at least two cardiovascular risk factors including: hypertension, dyslipidemia, smoking active or interrupted for less than 3 years, family history (relatives of the 1st degree) Accident major CV before 60.~* Or whatever the level of risk factors: peripheral artery disease and / or carotid atherosclerosis, or proteinuria~Exclusion Criteria:~* Valvular heart disease (severe to moderate valvular ) , hypertrophic , dilated , chronic lung~* History of cardiotoxic chemotherapy~* Atrioventricular blocks of degree~* Asthma~* Recent stroke within a month~* Bilateral carotid stenosis tight~* Glaucoma untreated narrow angle~* Subject to exclusion period (determined by a previous study or in progress)~* Inability to give informed about information~* patient under judicial protection~* patient guardianship or curatorship~* Current pregnancy (women of childbearing age )~* Breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues